Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how generic price pressures, specialty drug launches, and FDA inspections shape Amneal Pharmaceuticals can be daunting when each SEC filing tops 200 pages. Stock Titan decodes Amneal Pharmaceuticals SEC filings explained simply so you can spot what matters—whether it’s patent litigation disclosures or segment profit shifts.
Our AI reviews every document the moment it hits EDGAR, turning the Amneal Pharmaceuticals annual report 10-K simplified and each Amneal Pharmaceuticals quarterly earnings report 10-Q filing into concise takeaways. Need real-time alerts? Form 4 dashboards surface Amneal Pharmaceuticals Form 4 insider transactions real-time so you know when executives buy or sell ahead of an approval 8-K. We also map risk factors, R&D spending, and AvKARE contract metrics to clear, searchable tags.
Use the platform to:
- Review Amneal Pharmaceuticals insider trading Form 4 transactions alongside peer benchmarks.
- Dive into Amneal Pharmaceuticals proxy statement executive compensation and compare pay to pipeline milestones.
- Read AI notes that make Amneal Pharmaceuticals 8-K material events explained in minutes, not hours.
- Export tables from any Amneal Pharmaceuticals earnings report filing analysis directly to your model.
- Ask natural questions like “understanding Amneal Pharmaceuticals SEC documents with AI” and receive instant answers.
With comprehensive coverage, timely updates, and investor-ready summaries, our platform turns dense disclosures into practical insight—so you can focus on decisions rather than document hunts.
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported the sale of Class A common stock on 08/12/2025. The filing shows 33,436 shares were disposed in one or more transactions at a weighted average price of approximately $9.05 per share, with individual trade prices ranging from $9.05 to $9.07.
After these transactions, Boyer directly beneficially owns 256,670 shares. The Form 4 discloses no derivative transactions and includes a footnote stating the sales were executed in multiple transactions and that the reporting person will provide detailed per-price allocation upon request.
Amneal Pharmaceuticals (AMRX) filed a Form 144 disclosing a proposed sale of 169,206 common shares, with an aggregate market value of $1,568,539.00, to occur approximately on 08/13/2025 on NASDAQ through Charles Schwab Corp. The filing shows the shares were acquired by RSU vesting in March 2023 in three tranches: 87,719 on 03/12/2023, 36,197 on 03/01/2023 and 45,290 on 03/03/2023. The notice also records a sale during the past three months: Anastasios Konidaris sold 111,635 shares on 08/13/2025 for gross proceeds of $1,021,157.97. The signee represents there is no undisclosed material adverse information.
Amneal Pharmaceuticals (AMRX) submitted a Rule 144 notice reporting a proposed sale of 111,635 common shares with an aggregate market value of $1,006,947.00. The sale is planned on NASDAQ through Charles Schwab (3000 Schwab Way, Westlake, TX) with an approximate sale date of 08/13/2025. The filing shows 314,079,309 shares outstanding for the issuer.
The shares to be sold were acquired via RSU vesting on 03/01/2022 (23,916 shares) and 03/12/2022 (87,719 shares). The filer reports no securities sold in the past three months. The notice includes the standard representation that the filer does not possess undisclosed material adverse information and references trading-plan/Rule 10b5-1 considerations.
Amneal Pharmaceuticals (AMRX) Form 144 discloses a proposed sale of 33,436 Common Class A shares through Charles Schwab (3000 Schwab Way, Westlake, TX) with an aggregate market value of $304,100.00. The filing reports 314,079,309 shares outstanding and lists the approximate sale date as 08/12/2025 on NASDAQ. The shares were acquired as restricted stock awards from the issuer on 03/03/2025 (14,779 shares) and 03/04/2025 (18,657 shares) and were paid via Equity Compensation. The filer reports Nothing to Report for securities sold in the past three months and includes the standard representation that no material nonpublic information is known.
Amneal Pharmaceuticals (AMRX) Form 144 reports a proposed sale of 22,000 Class A shares through Merrill Lynch with an approximate sale date of 08/12/2025 and an aggregate market value of $198,000. The filing shows the shares were acquired on 03/03/2025 as equity compensation from Amneal Pharmaceuticals and that payment was made on the same date.
The filing lists 18,067,134 shares outstanding and indicates there were no securities sold by the person in the past three months. The filer also represents that they have no undisclosed material adverse information about the issuer.
Form 144 filing for Amneal Pharmaceuticals (AMRX) reports a proposed insider sale of 50,000 shares of common stock with an aggregate market value of $453,000. The filing lists 314,079,309 shares outstanding, and the approximate date of sale is 08/12/2025 on Nasdaq. The shares were originally acquired on 07/05/2018 as equity compensation.
The filing also discloses a recent sale of 49,140 shares on 05/16/2025 generating $370,541, and includes the standard insider representation that the seller is not aware of any undisclosed material adverse information. The notice documents compliance with Rule 144 procedures but does not provide additional operational or financial data.
Chirag K. Patel reports beneficial ownership of 22,180,421 shares of Amneal Pharmaceuticals Class A common stock, representing 7.1% of the class based on 314,079,309 shares outstanding. Of that total, Mr. Patel directly owns 857,980 shares and holds options for 24,977 and 28,044 shares; trusts he controls hold 21,269,420 shares. The filing states no transactions in the past 60 days and shows sole voting and dispositive power over the reported shares.
The filing also discloses an Omnibus Amendment to the Margin Loan Agreement and Pledge and Security Agreement dated August 6, 2025, which increases the collateral pledged to 19,000,000 shares and extends the loan maturity to April 29, 2028. The amended Pledge and Security Agreement is filed as an exhibit.
FAQ
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
What is the market cap of Amneal Pharmaceuticals (AMRX)?
